ARTICLE | Emerging Company Profile
Asher Bio: aiming cytokine therapies at specific immune cells
Emerging Company Profile: Asher Bio engineering cytokine specificity with Third Rock-led $55 million series A
March 25, 2021 11:06 PM UTC
Asher Bio emerged from stealth Tuesday with a $55 million series A led by Third Rock and a platform to improve the safety and efficacy of cytokine therapies for cancer.
Boxer Capital, Invus and seed investors Y Combinator and MBC Biolabs also participated in Asher Biotherapeutics Inc.’s A round...
BCIQ Company Profiles
BCIQ Target Profiles